相似文献
1
Biomarkers of Parkinson's disease: current status and future perspectives.
Drug Discov Today. 2013 Feb;18(3-4):155-62. doi: 10.1016/j.drudis.2012.09.001. Epub 2012 Sep 11.
2
New markers in Parkinson's disease.
Adv Clin Chem. 2020;96:137-178. doi: 10.1016/bs.acc.2019.12.001. Epub 2020 Jan 2.
3
Biomarkers in Parkinson's disease: Advances and strategies.
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1(Suppl 1):S106-10. doi: 10.1016/j.parkreldis.2015.09.048. Epub 2015 Sep 30.
4
The Concept of Prodromal Parkinson's Disease.
J Parkinsons Dis. 2015;5(4):681-97. doi: 10.3233/JPD-150685.
5
Biomarkers of cognitive decline in Parkinson's disease.
Parkinsonism Relat Disord. 2015 May;21(5):431-43. doi: 10.1016/j.parkreldis.2015.02.010. Epub 2015 Feb 20.
6
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease.
J Parkinsons Dis. 2024;14(s2):S353-S365. doi: 10.3233/JPD-230385.
7
Combining Biomarkers with Genetics In Prodromal/Earliest Phase Parkinson's Disease.
J Parkinsons Dis. 2024;14(s2):S345-S351. doi: 10.3233/JPD-240155.
8
Biomarkers of Parkinson's Disease: An Introduction.
Int Rev Neurobiol. 2017;132:183-196. doi: 10.1016/bs.irn.2017.03.003. Epub 2017 May 3.
9
Biomarkers of Nonmotor Symptoms in Parkinson's Disease.
Int Rev Neurobiol. 2017;133:259-289. doi: 10.1016/bs.irn.2017.05.020. Epub 2017 Jun 27.
10
From Rapid Eye Movement Sleep Behavior Disorder to Parkinson's Disease: Possible Predictive Markers of Conversion.
ACS Chem Neurosci. 2019 Feb 20;10(2):824-827. doi: 10.1021/acschemneuro.8b00388. Epub 2018 Oct 1.
引用本文的文献
1
Development of a hydroxyflavone-labelled 4554W peptide probe for monitoring αS aggregation.
Sci Rep. 2023 Jul 6;13(1):10968. doi: 10.1038/s41598-023-37655-3.
2
The reconfiguration pattern of individual brain metabolic connectome for Parkinson's disease identification.
MedComm (2020). 2023 Jun 27;4(4):e305. doi: 10.1002/mco2.305. eCollection 2023 Aug.
3
Serum metabolomics analysis revealed metabolic disorders in Parkinson's disease.
Medicine (Baltimore). 2023 Jun 9;102(23):e33715. doi: 10.1097/MD.0000000000033715.
4
Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson's disease.
Neural Regen Res. 2023 May;18(5):1107-1117. doi: 10.4103/1673-5374.355816.
5
Multilayer Exponential Family Factor models for integrative analysis and learning disease progression.
Biostatistics. 2023 Dec 15;25(1):203-219. doi: 10.1093/biostatistics/kxac042.
6
Brain age vector: A measure of brain aging with enhanced neurodegenerative disorder specificity.
Hum Brain Mapp. 2022 Nov;43(16):5017-5031. doi: 10.1002/hbm.26066. Epub 2022 Sep 12.
7
The Metabolomic Approach Reveals the Alteration in Human Serum and Cerebrospinal Fluid Composition in Parkinson's Disease Patients.
Pharmaceuticals (Basel). 2021 Sep 17;14(9):935. doi: 10.3390/ph14090935.
8
Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.
Diagnostics (Basel). 2020 May 25;10(5):339. doi: 10.3390/diagnostics10050339.
9
A Fully Automatic Framework for Parkinson's Disease Diagnosis by Multi-Modality Images.
Front Neurosci. 2019 Aug 23;13:874. doi: 10.3389/fnins.2019.00874. eCollection 2019.
10
Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models.
Cell Death Dis. 2018 Oct 3;9(10):1020. doi: 10.1038/s41419-018-1066-z.
本文引用的文献
1
A molecular signature in blood identifies early Parkinson's disease.
Mol Neurodegener. 2012 May 31;7:26. doi: 10.1186/1750-1326-7-26.
2
Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients.
Chin Med J (Engl). 2012 Feb;125(4):583-7.
3
Phosphorylated α-synuclein in Parkinson's disease.
Sci Transl Med. 2012 Feb 15;4(121):121ra20. doi: 10.1126/scitranslmed.3002566.
4
Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.
Neurology. 2012 Jan 3;78(1):55-61. doi: 10.1212/WNL.0b013e31823ed101. Epub 2011 Dec 14.
5
Do we still need to develop new imaging biomarkers of dopamine denervation for Parkinson's disease?
Exp Neurol. 2012 Jan;233(1):118-20. doi: 10.1016/j.expneurol.2011.10.008. Epub 2011 Oct 20.
6
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.
Neurobiol Aging. 2012 Apr;33(4):836.e5-7. doi: 10.1016/j.neurobiolaging.2011.09.015. Epub 2011 Oct 21.
7
Imaging biomarkers in Parkinson's disease.
Prog Neurobiol. 2011 Dec;95(4):614-28. doi: 10.1016/j.pneurobio.2011.08.009. Epub 2011 Aug 30.
8
[Expression of GSK3B gene in peripheral blood in patient with Parkinson's disease].
Mol Biol (Mosk). 2011 May-Jun;45(3):459-63.
9
Amyloid-β and τ biomarkers in Parkinson's disease-dementia.
J Neurol Sci. 2011 Nov 15;310(1-2):25-30. doi: 10.1016/j.jns.2011.06.046. Epub 2011 Jul 20.
10
Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.
Arch Neurol. 2011 Jul;68(7):932-7. doi: 10.1001/archneurol.2011.141.
Zotero 插件